Journal Information
Vol. 158. Issue 7.
Pages 341-342 (April 2022)
Vol. 158. Issue 7.
Pages 341-342 (April 2022)
Scientific letter
Vitiligo as durvalumab's immune-related adverse event in lung cancer
Vitíligo como evento adverso inmunomediado secundario a durvalumab en cáncer de pulmón
Visits
3
a Medical Oncology Department, Hospital Universitario Infanta Leonor, Gran vía del este, 80, 28031 Madrid, Spain
b Dermatology Department, Hospital Universitario Infanta Leonor, Gran vía del este, 80, 28031 Madrid, Spain
c Pathology Department, Hospital Universitario Infanta Leonor, Gran vía del este, 80, 28031 Madrid, Spain
d Universidad Complutense de Madrid, Madrid, Spain
This item has received
Article information
These are the options to access the full texts of the publication Medicina Clínica (English Edition)
Subscriber
Subscribe
Purchase
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail